Press Releases

Date Title and Summary View
Toggle Summary Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom
FREMONT, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Inc. (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using our proprietary ADAM technology, presented additional data
View HTML
Toggle Summary Zosano to Present Migraine Data at Three Industry-Leading Conferences
Late-Breaking Oral and Oral Presentations to feature M207 Acute Migraine Therapy Zotrip Pivotal Trial Data Selected by Headache Society and Drug Delivery Meetings FREMONT, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a specialty pharmaceutical company that
View HTML
Toggle Summary Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes
Pivotal trial of M207 meets co-primary endpoints to establish fast and durable pain relief $29.3 million follow-on offering of common stock provides funding for initiating required safety study and meeting pre-commercialization CMC/ manufacturing criteria Zosano names John P.
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update
FREMONT, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that it will host a conference call
View HTML
Toggle Summary Zosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Over-Allotment Option
FREMONT, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the closing of
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on developing an acute migraine treatment with a differentiated efficacy profile using the Company's proprietary transdermal delivery system, today announced the pricing of
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update
FREMONT, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging central nervous system company focused on providing symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the fourth
View HTML
Toggle Summary Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
41.5% of patients experienced freedom from pain at 2 hours vs. 14.3% for placebo (p 68.3% of patients experienced freedom from most bothersome symptom at 2 hours vs. 42.9% for placebo (p 26.8% of patients experienced freedom from pain at 1 hour vs. 10.4% for placebo (p FREMONT, Calif., Feb.
View HTML
Toggle Summary Zosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
FREMONT, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced that it has approved an inducement grant of options
View HTML
Toggle Summary Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
FREMONT, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced that the last subject has been treated in the
View HTML